Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of
linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to
stable treatment in elderly patients with T2DM with insufficient glycaemic control